Clinicians split on retatrutide expanded access program

The wire

1. 01Medscape reports clinicians disagree about the value and risks of an expanded access route to retatrutide ahead of approval.
2. 02Prescribers and telehealth operators fielding patient requests for pre-approval access need a position on eligibility and monitoring.
3. 03Expanded access does not generate controlled efficacy or safety data, so questions about durability and adverse events remain open until registrational results are published.

From the source

Retatrutide Expanded Access Draws Mixed Clinician Views